FDA of­fi­cials raise con­cerns with im­munother­a­py overuse for ear­ly-stage can­cer pa­tients: #AACR24

SAN DIEGO — As im­munother­a­pies be­come more wide­ly used be­fore and af­ter can­cer surgery, the FDA is wor­ried that some pa­tients may be re­ceiv­ing the ther­a­pies even when they don’t need them.

Im­mune check­point in­hibitors, such as Mer­ck’s Keytru­da and Bris­tol My­ers Squibb’s Op­di­vo, have be­come sta­ples in can­cer care in the past decade, and in 2023, Keytru­da was the world’s top-sell­ing drug. Their use has ex­pand­ed as phar­ma com­pa­nies have won ap­provals of the drugs in ear­li­er-stage can­cers by pair­ing them with surgery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER